1
Clinical Trials associated with SNK-396Phase 1, Single Multiple Dose Escalation Study in a Randomized, Double-blind, Placebo Controlled Design to Investigate Safety, Tolerability, PK and PD of SC Administered SNK-396 in Subjects With Elevated Low-Density Lipoprotein Cholesterol
This is a Phase 1, multi-center, randomized, double-blinded, placebo-controlled single and multiple dose escalation study with SC doses of SNK-396 in participants with elevated LDL-C. The study will be divided into two parts:
SAD cohorts
MAD cohorts
100 Clinical Results associated with SNK-396
100 Translational Medicine associated with SNK-396
100 Patents (Medical) associated with SNK-396
100 Deals associated with SNK-396